Structured programs for the management of patients with non-alcoholic fatty liver disease in the work of a general practitioner

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Non-alcoholic fatty liver disease (NAFLD) is the leading cause of chronic liver diseases that affect >25% of the world’ population. NAFLD is associated with substantial morbidity and mortality of liver cirrhosis, hepatocellular carcinoma, diabetes mellitus, and cardiovascular diseases, which leads to a significant healthcare burden and a decrease in quality of life in a patient. According to international guidelines, lifestyle modification for weight loss remains the first-line intervention in patients with NAFLD. The article summarizes evidence-based recommendations for lifestyle changes and clinical management of patients with NAFLD.

Full Text

Restricted Access

About the authors

V. V Skvortsov

Volgograd State Medical University, Ministry of Health of Russia

Author for correspondence.
Email: vskvortsov1@ya.ru
Professor

M. N Ustinova

Volgograd State Medical University, Ministry of Health of Russia

Email: vskvortsov1@ya.ru

References

  1. EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol. 2016; 64 (6): 1388-402. doi: 10.1016/j.jhep.2015.11.004
  2. Селиверстов П.В., Радченко В.Г. Роль митохондриальной цитопатии при стеатозе у больных неалкогольной жировой болезнью печени. Эффективная фармакотерапия. 2017; 16: 16-24.
  3. Селиверстов П.В. Ожирение как фактор риска развития сердечно-сосудистых осложнений на фоне неалкогольной жировой болезни печени. Медицинский альманах. 2016; 1 (41): 61-3.
  4. Селиверстов П.В., Джадхав С.Н., Цурцумия Д.Б. и др. Неалкогольная жировая болезнь печени: возможности диагностики. РМЖ. 2019; 5: 36-40.
  5. Лазебник Л.Б., Голованова Е.В., Туркина С.В. и др. Неалкогольная жировая болезнь печени у взрослых: клиника, диагностика, лечение. Рекомендации для терапевтов, третья версия. Экспериментальная и клиническая гастроэнтерология. 2021; 1 (1): 4-52. doi: 10.31146/1682-8658-ecg-185-1-4-52
  6. Abenavoli L., Greco M., Milic N.et al. Effect of Mediterranean Diet and Antioxidant Formulation in Non-Alcoholic Fatty Liver Disease: A Randomized Study. Nutrients. 2017; 9 (8): 870. doi: 10.3390/nu9080870
  7. Torres M.C.P., Bodini G., Furnari M. et al. Nuts and NonAlcoholic Fatty Liver Disease: Are Nuts Safe for Patients with Fatty Liver Disease? Nutrients. 2020; 12: 3363. DOI: 10.3390/ nu12113363
  8. Byrne C.D., Targher G. NAFLD: a multisystem disease. J Hepatol. 2015; 62 (1 Suppl): S47-64. doi: 10.1016/j.jhep.2014.12.012
  9. Yaskolka Meir A., Rinott E., Tsaban G. et al. Effect of green-Mediterranean diet on intrahepatic fat: the DIRECT PLUS randomised controlled trial. Gut. 2021; 70 (11): 2085-95. doi: 10.1136/gutjnl-2020-323106
  10. Cabo R., Mattson M.P. Effects of intermittent fasting on health, aging, and disease. N Engl J Med. 2019; 381 (26): 2541-51. doi: 10.1056/NEJMra1905136
  11. Klempel M.C., Kroeger C.M., Bhutani S. et al.Intermittent fasting combined with calorie restriction is effective for weight loss and cardio-protection in obese women. Nutr J. 2021; 11: 98. doi: 10.1186/1475-2891-11-98
  12. Holmer M., Lindqvist C., Petersson S. et al. Treatment of NAFLD with intermittent calorie restriction or low-carb high-fat diet - a randomised controlled trial. JHEP Rep. 2021; 3 (3): 100256. doi: 10.1016/j.jhepr.2021.100256
  13. Shim S.G., Jun D.W., Kim E.K. et al. Caffeine attenuates liver fibrosis via defective adhesion of hepatic stellate cells in cirrhotic model. J Gastroenterol Hepatol. 2013; 28 (12): 1877-84. doi: 10.1111/jgh.12317
  14. Dunn W., Sanyal A.J., Brunt E.M. et al. Modest alcohol consumption is associated with decreased prevalence of steatohepatitis in patients with non-alcoholic fatty liver disease (NAFLD). J Hepatol. 2012; 57 (2): 384-91. doi: 10.1016/j.jhep.2012.03.024
  15. Pezeshki A., Safi S., Feizi A. et al. The Effect of Green Tea Extract Supplementation on Liver Enzymes in Patients with Nonalcoholic Fatty Liver Disease.Int J Prev Med. 2016; 7: 28. doi: 10.4103/2008-7802.173051
  16. Munzel T., S0rensen M., Gori T. et al. Environmental stressors and cardio-metabolic disease: part I, II. Eur Heart J. 2017; 38 (8): 550-64. doi: 10.1093/eurheartj/ehw269
  17. Kang D., Zhao D., Ryu S. et al. Perceived stress and non-alcoholic fatty liver disease in apparently healthy men and women. Sci Rep. 2020; 10: 38. doi: 10.1038/s41598-019-57036-z
  18. Keating S.E., George J., Johnson N.A. The benefits of exercise for patients with nonalcoholic fatty liver disease. Expert Rev Gastroenterol Hepatol. 2015; 9 :1247-50. doi: 10.1586/17474124.2015.1075392
  19. Oh S., Shida T., Yamagishi K. et al. Moderate to vigorous physical activity volume is an important factor for managing nonalcoholic fatty liver disease: a retrospective study. Hepatology. 2015; 61: 1205-15. doi: 10.1002/hep.27544
  20. Soto-Angona O., Anmella G., Valdes-Florido M.J. et al. Non-alcoholic fatty liver disease (NAFLD) as a neglected metabolic companion of psychiatric disorders: common pathways and future approaches. BMC Med. 2020; 18: 261. doi: 10.1186/s12916-020-01713-8
  21. Jung H.-S., Chang Y., Kwon M.-J. et al. Smoking and the risk of non-alcoholic fatty liver disease: a cohort study. Am J Gastroenterol. 2019; 114: 453-63. doi: 10.1038/s41395- 018-0283-5
  22. Lazo M., Solga S.F., Horska A. et al. Effect of a 12-month intensive lifestyle intervention on hepatic steatosis in adults with type 2 diabetes. Diabetes Care. 2010; 33 (10): 2156-63. doi: 10.2337/dc10-0856
  23. George A.St., Bauman A., Johnston A. et al. Effect of a lifestyle intervention in patients with abnormal liver enzymes and metabolic risk factors. J Gastroenterol Hepatol. 2009; 24 (3): 399-407. doi: 10.1111/j.1440-1746.2008.05694.x

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies